CN113573702A - 用于癌症治疗的亚达司他的组合 - Google Patents
用于癌症治疗的亚达司他的组合 Download PDFInfo
- Publication number
- CN113573702A CN113573702A CN202080018266.2A CN202080018266A CN113573702A CN 113573702 A CN113573702 A CN 113573702A CN 202080018266 A CN202080018266 A CN 202080018266A CN 113573702 A CN113573702 A CN 113573702A
- Authority
- CN
- China
- Prior art keywords
- combination
- inhibitor
- cancer
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202511368496.2A CN121422229A (zh) | 2019-03-25 | 2020-03-25 | 用于癌症治疗的亚达司他的组合 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382206 | 2019-03-25 | ||
| EP19382206.1 | 2019-03-25 | ||
| PCT/EP2020/058362 WO2020193631A1 (en) | 2019-03-25 | 2020-03-25 | Combinations of iadademstat for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511368496.2A Division CN121422229A (zh) | 2019-03-25 | 2020-03-25 | 用于癌症治疗的亚达司他的组合 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113573702A true CN113573702A (zh) | 2021-10-29 |
Family
ID=66175363
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080018266.2A Pending CN113573702A (zh) | 2019-03-25 | 2020-03-25 | 用于癌症治疗的亚达司他的组合 |
| CN202511368496.2A Pending CN121422229A (zh) | 2019-03-25 | 2020-03-25 | 用于癌症治疗的亚达司他的组合 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511368496.2A Pending CN121422229A (zh) | 2019-03-25 | 2020-03-25 | 用于癌症治疗的亚达司他的组合 |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
| SI3941466T1 (sl) | 2019-03-20 | 2026-04-30 | Oryzon Genomics, S.A. | Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018083138A1 (en) * | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9469597B2 (en) | 2011-10-20 | 2016-10-18 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| US11685782B2 (en) * | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
-
2020
- 2020-03-25 EP EP20712594.9A patent/EP3946295B1/en active Active
- 2020-03-25 BR BR112021016171-6A patent/BR112021016171A2/pt unknown
- 2020-03-25 MX MX2021011610A patent/MX2021011610A/es unknown
- 2020-03-25 WO PCT/EP2020/058362 patent/WO2020193631A1/en not_active Ceased
- 2020-03-25 CN CN202080018266.2A patent/CN113573702A/zh active Pending
- 2020-03-25 PH PH1/2021/552326A patent/PH12021552326A1/en unknown
- 2020-03-25 CA CA3132473A patent/CA3132473A1/en active Pending
- 2020-03-25 CN CN202511368496.2A patent/CN121422229A/zh active Pending
- 2020-03-25 SG SG11202109025XA patent/SG11202109025XA/en unknown
- 2020-03-25 AU AU2020249493A patent/AU2020249493B2/en active Active
- 2020-03-25 KR KR1020217028840A patent/KR20210142614A/ko not_active Ceased
- 2020-03-25 JP JP2021557187A patent/JP7824627B2/ja active Active
- 2020-03-25 US US17/441,758 patent/US20220175698A1/en active Pending
-
2021
- 2021-09-13 IL IL286353A patent/IL286353A/en unknown
-
2026
- 2026-02-13 JP JP2026021790A patent/JP2026077769A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018083138A1 (en) * | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
Non-Patent Citations (2)
| Title |
|---|
| JUNZO HAMANISHI等: "PD-1/PD-L1 blockade in cancer treatment: perspectives and issues", 《INT J CLIN ONCOL》, vol. 21, 22 February 2016 (2016-02-22), pages 1 * |
| WANQIANG SHENG等: "LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade", 《CELL》, vol. 174, 26 July 2018 (2018-07-26), pages 7 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7824627B2 (ja) | 2026-03-05 |
| SG11202109025XA (en) | 2021-09-29 |
| JP2026077769A (ja) | 2026-05-13 |
| KR20210142614A (ko) | 2021-11-25 |
| AU2020249493A1 (en) | 2021-09-16 |
| PH12021552326A1 (en) | 2022-06-27 |
| JP2022526525A (ja) | 2022-05-25 |
| EP3946295A1 (en) | 2022-02-09 |
| BR112021016171A2 (pt) | 2021-10-05 |
| CA3132473A1 (en) | 2020-10-01 |
| CN121422229A (zh) | 2026-01-30 |
| US20220175698A1 (en) | 2022-06-09 |
| WO2020193631A1 (en) | 2020-10-01 |
| EP3946295B1 (en) | 2026-08-05 |
| AU2020249493B2 (en) | 2025-08-28 |
| IL286353A (en) | 2021-10-31 |
| MX2021011610A (es) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517549A5 (cg-RX-API-DMAC7.html) | ||
| JP2022531939A (ja) | がんを処置する方法 | |
| IL263110B (en) | Combined treatment of notch and pd-1 or pd-l1 inhibitors | |
| US12427142B2 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| JP2026077769A (ja) | 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物 | |
| CN104684579A (zh) | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 | |
| CN120826242A (zh) | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| JP2022547061A5 (cg-RX-API-DMAC7.html) | ||
| RU2833564C2 (ru) | Комбинации иададемстата для лечения рака | |
| TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
| TWI671072B (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 | |
| TWI882612B (zh) | 藥物組合及其應用 | |
| US20250302781A1 (en) | Method for pretreating relapsing cancer | |
| KR102356393B1 (ko) | 두경부암의 치료 또는 예방에 사용하기 위한 pi3 키나제 억제제와 파클리탁셀의 조합물 | |
| TW201944997A (zh) | 西達本胺與依西美坦在製備用於治療乳腺癌的聯合用藥物中的用途及聯合用藥物 | |
| US20030139430A1 (en) | Use of organic compounds | |
| JP2025516649A5 (cg-RX-API-DMAC7.html) | ||
| TH2201001953A (th) | การรักษาของโรคตับอักเสบจากแอลกอฮอล์ | |
| HK40015395A (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |